SCHEDULE: Bigger Capital Discloses 5.75% Stake in Protagenic Therapeutics

Bigger Capital Fund L.P., along with its general partner Bigger Capital Fund GP, LLC and managing member Michael Bigger, has disclosed a beneficial ownership of 5.75% in Protagenic Therapeutics, Inc., totaling 50,000 shares of common stock.

Summary

• Bigger Capital Fund L.P., Bigger Capital Fund GP, LLC, and Michael Bigger collectively reported beneficial ownership of 50,000 shares of Protagenic Therapeutics, Inc. Common Stock.
• This ownership represents approximately 5.75% of the outstanding Common Stock of Protagenic Therapeutics, Inc.
• The percentage is calculated based on 868,414 shares of Common Stock outstanding, as reported in the Issuer's Proxy Statement filed on May 19, 2025.
• The event triggering this filing occurred on July 2, 2025.
• The reporting persons certified that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, except for activities related to a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: Neutral. A Schedule 13G is a factual disclosure of ownership and does not inherently convey positive or negative sentiment about the company's performance or prospects.

Industry Context

This filing indicates a significant passive investment by Bigger Capital in Protagenic Therapeutics, a common occurrence in the financial markets where investment funds acquire stakes in publicly traded companies. It does not inherently suggest a strategic shift or industry trend beyond standard investment activity.

Stakeholder Impact

• Shareholders: The disclosure of a new significant shareholder could be viewed positively by some investors as a vote of confidence, or neutrally as a standard investment. It provides transparency regarding the ownership structure.

Key Dates

Keywords

Protagenic Therapeutics, Bigger Capital Fund, Michael Bigger, Schedule 13G, Beneficial Ownership, Common Stock, Equity Stake, SEC Filing, Investment, Biotechnology